Lung Cancer Clinical Trial: Lenvatinib (E7080) for KIF5B-RET-Positive NSCLC
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 27, 2015
- 1 min read
A Phase 2 clinical trial evaluating lenvatinib (E7080), a targeted therapy agent, in KIF5B-RET-positive lung cancer patients is being conducted across Taiwan, Japan, the United States, Hong Kong, and Thailand.
Trial Period: April 2013 – April 2016 Target Enrollment: At least 20 subjects with KIF5B-RET translocation
Eligibility Criteria:
- Age 18 or older
- Diagnosed with lung cancer
- KIF5B or RET translocation confirmed
- Able to receive treatment
- Measurable tumor by RECIST 1.1 criteria
- Blood pressure controlled
- Performance status (PS) 0 or 1
Exclusion Criteria:
- Received other anti-tumor agents within 21 days prior to first lenvatinib dose
- Severe unrecovered adverse events from prior anti-tumor therapy
- Serious cardiac disease
- Gastrointestinal dysfunction
- Surgery within 3 weeks prior to first lenvatinib dose
Trial Description (English):
This is a Phase 2, open-label, safety and activity study of lenvatinib in subjects with KIF5B-RET-positive adenocarcinoma of the lung and other confirmed RET translocations. At least 20 subjects with KIF5B-RET will be treated and will receive lenvatinib at a starting dose of 24 mg orally, once per day. Additional subjects with other RET translocations will be treated with lenvatinib at a starting dose of 24 mg orally, once per day. (ClinicalTrials.gov)
Source: http://www.eisai.co.jp/news/news201435pdf.pdf
Lung Cancer | RET-Positive | Targeted Therapy | Lenvatinib
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4